171 related articles for article (PubMed ID: 20016227)
1. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Oncology; 2009; 77(6):342-8. PubMed ID: 20016227
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
3. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
5. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
Taieb S; Trillet-Lenoir V; Rambaud L; Descos L; Freyer G
Cancer; 2002 May; 94(9):2434-40. PubMed ID: 12015768
[TBL] [Abstract][Full Text] [Related]
6. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin and axonal Na+ channel function in vivo.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
[TBL] [Abstract][Full Text] [Related]
8. [Lhermitte's sign in three oncological patients].
Porta-Etessam J; Martínez-Salio A; Berbel A; Balsalobre-Aznar J; Esteban J; Benito-León J; Ruiz J
Rev Neurol; 2000 Apr 1-15; 30(7):649-51. PubMed ID: 10859744
[TBL] [Abstract][Full Text] [Related]
9. Reassessment of Lhermitte's sign in multiple sclerosis.
Beckmann Y; Özakbaş S; Bülbül NG; Kösehasanoğulları G; Seçil Y; Bulut O; İncesu TK; Tokuçoğlu F; Ertekin C
Acta Neurol Belg; 2015 Dec; 115(4):605-8. PubMed ID: 25841671
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
[TBL] [Abstract][Full Text] [Related]
11. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
Park SB; Lin CS; Kiernan MC
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-related Lhermitte's sign.
Inbar M; Merimsky O; Wigler N; Chaitchik S
Anticancer Drugs; 1992 Aug; 3(4):375-7. PubMed ID: 1421433
[TBL] [Abstract][Full Text] [Related]
13. Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.
Heide R; Bostock H; Ventzel L; Grafe P; Bergmans J; Fuglsang-Frederiksen A; Finnerup NB; Tankisi H
Clin Neurophysiol; 2018 Mar; 129(3):694-706. PubMed ID: 29233604
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging and posttraumatic Lhermitte's sign.
Traynelis VC; Hitchon PW; Yuh WT; Kaufman HH
J Spinal Disord; 1990 Dec; 3(4):376-9. PubMed ID: 2134451
[TBL] [Abstract][Full Text] [Related]
15. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
[TBL] [Abstract][Full Text] [Related]
16. 'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin.
Jurado JM; Pajares B; Olmos D; Sevilla I; Alba E
Ann Oncol; 2008 Dec; 19(12):2093-4. PubMed ID: 18977850
[No Abstract] [Full Text] [Related]
17. Delayed oxaliplatin-induced sensorimotor polyneuropathy.
Nardone R; Buratti T; Golaszewski S; Bratti A; Caleri F; Tezzon F; Ladurner G; Mitterer M
Onkologie; 2009 May; 32(5):283-5. PubMed ID: 19420977
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin-Induced Lhermitte's Sign in Gastric Cancer.
Okamoto T; Takagi K; Fukuda K
Case Rep Oncol Med; 2020; 2020():8826657. PubMed ID: 32670652
[TBL] [Abstract][Full Text] [Related]
19. Lhermitte's sign as a presenting symptom of primary spinal cord tumor.
Newton HB; Rea GL
J Neurooncol; 1996 Aug; 29(2):183-8. PubMed ID: 8858524
[TBL] [Abstract][Full Text] [Related]
20. Lhermitte's phenomenon and platinum, beware of latency.
O'Reilly A; Ryan S; MacEneaney P; O'Reilly SP; Cronin S; Power DG
Oncol Res Treat; 2014; 37(10):591-4. PubMed ID: 25342510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
